<p>IFP Advisors Inc 在最近向證券交易委員會（SEC）披露的文件中表示，在第二季度將其在 Orchestra BioMed Holdings, Inc.（NASDAQ:OBIO - 免費報告）中的持股減少了 47.3%。該公司在此期間出售了 76,563 股後，持有 85,358 股該公司的股票。IFP Advisors Inc 在最近一個季度末持有的 Orchestra BioMed 股票約佔 0.22%，價值 229,000 美元。</p>
<p>獲取 <strong>Orchestra BioMed</strong> 的提醒：</p>
<p>其他一些對沖基金也增加或減少了對該公司的投資。Nuveen LLC 在第一季度新購入了價值約 179,000 美元的 Orchestra BioMed 股票。德意志銀行在第一季度將其在 Orchestra BioMed 的持股增加了 67.3%。德意志銀行目前持有 20,219 股該公司的股票，價值 87,000 美元，此前在上個季度又購買了 8,134 股。最後，美國銀行在第四季度將其在 Orchestra BioMed 的持股提高了 42.0%。美國銀行目前持有 23,780 股該公司的股票，價值 95,000 美元，此前在上個季度又購買了 7,036 股。目前，53.20% 的股票由機構投資者持有。</p>
<h2>分析師設定新目標價</h2>
<p>一些研究公司最近對 OBIO 發表了看法。Weiss Ratings 在 10 月 8 日的報告中重申了對 Orchestra BioMed 股票的 &#34;賣出（e+）&#34;評級。HC Wainwright 在 9 月 4 日的研究報告中將 Orchestra BioMed 的目標價從 12.00 美元下調至 10.00 美元，並對該股票給予了 &#34;買入&#34;評級。Chardan Capital 在 8 月 13 日的報告中重申了 &#34;買入&#34;評級，並將 Orchestra BioMed 股票的目標價設定為 20.00 美元。最後，BTIG Research 在 8 月 20 日的研究報告中重申了對 Orchestra BioMed 股票的 &#34;中性&#34;評級。一位研究分析師對該股票給予了強烈買入評級，三位分析師給予了買入評級，一位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，該股票目前的平均評級為 &#34;適度買入&#34;，平均目標價為 13.50 美元。</p>
<p><strong>查看我們最新的 OBIO 股票分析</strong></p>
<h2>內部人士買賣</h2>
<p>在其他 Orchestra BioMed 的新聞中，內部人士 David P. Hochman 在 8 月 4 日的交易中購買了 20,000 股該公司的股票。該股票的平均購買價格為每股 2.75 美元，總交易額為 55,000.00 美元。交易完成後，內部人士直接持有 349,331 股該公司的股票，價值 960,660.25 美元。這筆交易代表了他們持股的 6.07% 增加。該收購在向 SEC 的文件中披露，可以通過此超鏈接訪問。內部人士在上個季度購買了價值 100,384 美元的 37,760 股公司股票。8.10% 的股票由公司內部人士持有。</p>
<h2>Orchestra BioMed 股票上漲 0.5%</h2>
<p>NASDAQ OBIO 週五開盤價為 3.68 美元。該公司的 50 日移動平均線為 2.71 美元，200 日移動平均線為 2.85 美元。該公司的債務與股本比率為 48.76，流動比率為 2.10，速動比率為 2.09。該股票的市值為 1.422 億美元，市盈率為 -2.01，貝塔值為 0.60。Orchestra BioMed Holdings, Inc. 的一年低點為 2.20 美元，一年高點為 6.50 美元。</p>
<p>Orchestra BioMed（NASDAQ:OBIO - 獲取免費報告）最近在 8 月 12 日發佈了其財報。該公司報告本季度每股收益為（0.50）美元，超出分析師的共識預期（0.51）美元 0.01 美元。Orchestra BioMed 的淨利潤率為 -2,367.49%，股本回報率為 -289.42%。該公司本季度的收入為 84 萬美元，而分析師的預期為 78 萬美元。股票研究分析師預測，Orchestra BioMed Holdings, Inc. 本年度將發佈 -1.66 的每股收益。</p>
<h2>Orchestra BioMed 公司簡介</h2>
<p>（免費報告）</p>
<p>Orchestra BioMed Holdings, Inc. 是一家生物醫學創新公司。該公司的旗艦產品候選包括用於治療高血壓（HTN）的 BackBeat 心臟神經調節療法（CNT）；以及用於治療動脈粥樣硬化性動脈疾病的 Virtue Sirolimus AngioInfusion Balloon（SAB）。</p>
<h2>另請參閲</h2>
<ul>
<li>我們更看好的五隻股票比 Orchestra BioMed 更好</li>
<li>什麼是股票市場指數，如何使用它們？</li>
<li>Salesforce 期待已久的拐點來了：反彈開始！</li>
<li>NYSE 股票為投資者提供多種優質選擇</li>
<li>Rocket Lab USA 獲得華爾街的認可：現在是買入時機嗎？</li>
<li>在哪裏可以找到財報電話會議的記錄</li>
<li>Archer 收購競爭對手的專利寶藏，進行戰略性舉措</li>
</ul>
<p><strong>想看看其他對沖基金持有 OBIO 的情況嗎？</strong> 訪問 HoldingsChannel.com 獲取 Orchestra BioMed Holdings, Inc.（NASDAQ:OBIO - 免費報告）的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Orchestra BioMed 嗎？</h2>
<p>在考慮投資 Orchestra BioMed 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前... 而 Orchestra BioMed 並不在名單上。</p>
<p>雖然 Orchestra BioMed 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得買入。</p>
<p>在這裏查看這五隻股票</p>

OBIO

<p>IFP Advisors Inc 在第二季度減少了對 Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) 的持股比例，降幅為 47.3%，目前持有 85,358 股，價值 229,000 美元。其他對沖基金也調整了他們的持倉。分析師對 OBIO 的評級不一，平均目標價為 13.50 美元。內部人士 David P. Hochman 最近購買了 20,000 股。該股票目前交易價格為 3.68 美元，市值為 1.422 億美元，上一季度的每股收益為-0.50 美元</p>

<p>IFP Advisors Inc lowered its holdings in shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) by 47.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 85,358 shares of the company's stock after selling 76,563 shares during the period. IFP Advisors Inc owned approximately 0.22% of Orchestra BioMed worth $229,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>IFP Advisors Inc 在最近向證券交易委員會（SEC）披露的文件中表示，在第二季度將其在 Orchestra BioMed Holdings, Inc.（NASDAQ:OBIO - 免費報告）中的持股減少了 47.3%。該公司在此期間出售了 76,563 股後，持有 85,358 股該公司的股票。IFP Advisors Inc 在最近一個季度末持有的 Orchestra BioMed 股票約佔 0.22%，價值 229,000 美元。</p>
</div><p>Get <strong>Orchestra BioMed</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Orchestra BioMed</strong> 的提醒：</p>
</div><p>A number of other hedge funds have also added to or reduced their stakes in the business. Nuveen LLC acquired a new position in shares of Orchestra BioMed during the first quarter worth approximately $179,000. Deutsche Bank AG increased its stake in Orchestra BioMed by 67.3% during the 1st quarter. Deutsche Bank AG now owns 20,219 shares of the company's stock valued at $87,000 after purchasing an additional 8,134 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in Orchestra BioMed by 42.0% during the fourth quarter. Bank of America Corp DE now owns 23,780 shares of the company's stock worth $95,000 after buying an additional 7,036 shares during the last quarter. 53.20% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些對沖基金也增加或減少了對該公司的投資。Nuveen LLC 在第一季度新購入了價值約 179,000 美元的 Orchestra BioMed 股票。德意志銀行在第一季度將其在 Orchestra BioMed 的持股增加了 67.3%。德意志銀行目前持有 20,219 股該公司的股票，價值 87,000 美元，此前在上個季度又購買了 8,134 股。最後，美國銀行在第四季度將其在 Orchestra BioMed 的持股提高了 42.0%。美國銀行目前持有 23,780 股該公司的股票，價值 95,000 美元，此前在上個季度又購買了 7,036 股。目前，53.20% 的股票由機構投資者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>A number of research firms have recently weighed in on OBIO. Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Orchestra BioMed in a report on Wednesday, October 8th. HC Wainwright dropped their price objective on Orchestra BioMed from $12.00 to $10.00 and set a &#34;buy&#34; rating on the stock in a research note on Thursday, September 4th. Chardan Capital reaffirmed a &#34;buy&#34; rating and set a $20.00 price objective on shares of Orchestra BioMed in a report on Wednesday, August 13th. Finally, BTIG Research reiterated a &#34;neutral&#34; rating on shares of Orchestra BioMed in a research note on Wednesday, August 20th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $13.50.</p>
<div class="lb-trans"><p>一些研究公司最近對 OBIO 發表了看法。Weiss Ratings 在 10 月 8 日的報告中重申了對 Orchestra BioMed 股票的 &#34;賣出（e+）&#34;評級。HC Wainwright 在 9 月 4 日的研究報告中將 Orchestra BioMed 的目標價從 12.00 美元下調至 10.00 美元，並對該股票給予了 &#34;買入&#34;評級。Chardan Capital 在 8 月 13 日的報告中重申了 &#34;買入&#34;評級，並將 Orchestra BioMed 股票的目標價設定為 20.00 美元。最後，BTIG Research 在 8 月 20 日的研究報告中重申了對 Orchestra BioMed 股票的 &#34;中性&#34;評級。一位研究分析師對該股票給予了強烈買入評級，三位分析師給予了買入評級，一位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，該股票目前的平均評級為 &#34;適度買入&#34;，平均目標價為 13.50 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on OBIO</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 OBIO 股票分析</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士買賣</h2>
</div><p>In other Orchestra BioMed news, insider David P. Hochman bought 20,000 shares of the business's stock in a transaction on Monday, August 4th. The stock was purchased at an average price of $2.75 per share, for a total transaction of $55,000.00. Following the completion of the transaction, the insider directly owned 349,331 shares of the company's stock, valued at $960,660.25. This trade represents a 6.07% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders have bought 37,760 shares of company stock worth $100,384 over the last quarter. 8.10% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 Orchestra BioMed 的新聞中，內部人士 David P. Hochman 在 8 月 4 日的交易中購買了 20,000 股該公司的股票。該股票的平均購買價格為每股 2.75 美元，總交易額為 55,000.00 美元。交易完成後，內部人士直接持有 349,331 股該公司的股票，價值 960,660.25 美元。這筆交易代表了他們持股的 6.07% 增加。該收購在向 SEC 的文件中披露，可以通過此超鏈接訪問。內部人士在上個季度購買了價值 100,384 美元的 37,760 股公司股票。8.10% 的股票由公司內部人士持有。</p>
</div><h2>Orchestra BioMed Trading Up 0.5%</h2>
<div class="lb-trans"><h2>Orchestra BioMed 股票上漲 0.5%</h2>
</div><p>NASDAQ OBIO opened at $3.68 on Friday. The business's fifty day moving average is $2.71 and its 200-day moving average is $2.85. The company has a debt-to-equity ratio of 48.76, a current ratio of 2.10 and a quick ratio of 2.09. The stock has a market capitalization of $142.20 million, a price-to-earnings ratio of -2.01 and a beta of 0.60. Orchestra BioMed Holdings, Inc. has a one year low of $2.20 and a one year high of $6.50.</p>
<div class="lb-trans"><p>NASDAQ OBIO 週五開盤價為 3.68 美元。該公司的 50 日移動平均線為 2.71 美元，200 日移動平均線為 2.85 美元。該公司的債務與股本比率為 48.76，流動比率為 2.10，速動比率為 2.09。該股票的市值為 1.422 億美元，市盈率為 -2.01，貝塔值為 0.60。Orchestra BioMed Holdings, Inc. 的一年低點為 2.20 美元，一年高點為 6.50 美元。</p>
</div><p>Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.51) by $0.01. Orchestra BioMed had a negative net margin of 2,367.49% and a negative return on equity of 289.42%. The firm had revenue of $0.84 million for the quarter, compared to analysts' expectations of $0.78 million. Equities research analysts predict that Orchestra BioMed Holdings, Inc. will post -1.66 EPS for the current year.</p>
<div class="lb-trans"><p>Orchestra BioMed（NASDAQ:OBIO - 獲取免費報告）最近在 8 月 12 日發佈了其財報。該公司報告本季度每股收益為（0.50）美元，超出分析師的共識預期（0.51）美元 0.01 美元。Orchestra BioMed 的淨利潤率為 -2,367.49%，股本回報率為 -289.42%。該公司本季度的收入為 84 萬美元，而分析師的預期為 78 萬美元。股票研究分析師預測，Orchestra BioMed Holdings, Inc. 本年度將發佈 -1.66 的每股收益。</p>
</div><h2>Orchestra BioMed Company Profile</h2>
<div class="lb-trans"><h2>Orchestra BioMed 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.</p>
<div class="lb-trans"><p>Orchestra BioMed Holdings, Inc. 是一家生物醫學創新公司。該公司的旗艦產品候選包括用於治療高血壓（HTN）的 BackBeat 心臟神經調節療法（CNT）；以及用於治療動脈粥樣硬化性動脈疾病的 Virtue Sirolimus AngioInfusion Balloon（SAB）。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參閲</h2>
</div><ul>
<li>Five stocks we like better than Orchestra BioMed</li>
<li>What is a Stock Market Index and How Do You Use Them?</li>
<li>Salesforce’s Long-Awaited Inflection is Here: Rally On!</li>
<li>NYSE Stocks Give Investors a Variety of Quality Options</li>
<li>Rocket Lab USA Receives Wall Street Validation: Time to Buy?</li>
<li>Where to Find Earnings Call Transcripts</li>
<li>Archer Buys Rival's Patent Treasure Trove in Strategic Move</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Orchestra BioMed 更好</li>
<li>什麼是股票市場指數，如何使用它們？</li>
<li>Salesforce 期待已久的拐點來了：反彈開始！</li>
<li>NYSE 股票為投資者提供多種優質選擇</li>
<li>Rocket Lab USA 獲得華爾街的認可：現在是買入時機嗎？</li>
<li>在哪裏可以找到財報電話會議的記錄</li>
<li>Archer 收購競爭對手的專利寶藏，進行戰略性舉措</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding OBIO?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有 OBIO 的情況嗎？</strong> 訪問 HoldingsChannel.com 獲取 Orchestra BioMed Holdings, Inc.（NASDAQ:OBIO - 免費報告）的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=OBIO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Orchestra BioMed Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Orchestra BioMed 嗎？</h2>
</div><p>Before you consider Orchestra BioMed, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Orchestra BioMed 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orchestra BioMed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前... 而 Orchestra BioMed 並不在名單上。</p>
</div><p>While Orchestra BioMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Orchestra BioMed 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得買入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

IFP Advisors Inc 在 Orchestra BioMed Holdings, Inc. $OBIO 中持有 22.9 萬美元的頭寸